Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer

Synthetic oleanane triterpenoids and rexinoids are two new classes of multifunctional drugs. They are neither conventional cytotoxic agents, nor are they monofunctional drugs that uniquely target single steps in signal transduction pathways. Synthetic oleanane triterpenoids have profound effects on inflammation and the redox state of cells and tissues, as well as being potent anti-proliferative and pro-apoptotic agents. Rexinoids are ligands for the nuclear receptor transcription factors known as retinoid X receptors. Both classes of agents can prevent and treat cancer in experimental animals. These drugs have unique molecular and cellular mechanisms of action and might prove to be synergistic with standard anti-cancer treatments.

[1]  M. Sporn,et al.  A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. , 2002, Bioorganic & medicinal chemistry letters.

[2]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[3]  Irina Petrache,et al.  Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. , 2004, The Journal of clinical investigation.

[4]  D. Crowe,et al.  A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands , 2004, Breast Cancer Research.

[5]  M. Sporn,et al.  The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Caspase-Dependent and -Independent Apoptosis in Acute Myelogenous Leukemia , 2004, Cancer Research.

[6]  S. Hilsenbeck,et al.  The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. , 2005, Cancer research.

[7]  Michael Lehrke,et al.  The many faces of PPARgamma. , 2005, Cell.

[8]  R. Chandraratna,et al.  Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. , 2001, Journal of medicinal chemistry.

[9]  B. Bartel,et al.  Biosynthetic diversity in plant triterpene cyclization. , 2006, Current opinion in plant biology.

[10]  W. Lamph,et al.  A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer , 2006, The Prostate.

[11]  M. Sporn,et al.  Cancer chemoprevention: scientific promise, clinical uncertainty , 2005, Nature Clinical Practice Oncology.

[12]  K. Hymes,et al.  Bexarotene: a clinical review , 2004, Expert review of anticancer therapy.

[13]  M. Sporn,et al.  Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. , 2006, Bioorganic & medicinal chemistry letters.

[14]  S. Hilsenbeck,et al.  Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  V. Steele,et al.  Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. , 2004, Carcinogenesis.

[16]  M. Sporn,et al.  The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. , 2005, Cancer research.

[17]  Gregor Eichele,et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.

[18]  Giulio Superti-Furga,et al.  A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.

[19]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[20]  W. Lamph,et al.  Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). , 2000, Cancer research.

[21]  M. D. Leibowitz,et al.  Design, synthesis and structure-activity relationship of novel RXR-selective modulators. , 2004, Bioorganic & medicinal chemistry letters.

[22]  M. Konopleva,et al.  Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells , 2006, Molecular Cancer Therapeutics.

[23]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[24]  M. Sporn,et al.  The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor β-Dependent Apoptosis in Breast Cancer , 2004, Cancer Research.

[25]  M. Manson,et al.  Prospects for plant-derived chemopreventive agents exhibiting multiple mechanisms of action. , 2005, Current medicinal chemistry. Anti-cancer agents.

[26]  W. Lamph,et al.  The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma , 2005, Molecular Cancer Therapeutics.

[27]  S. Bernstein,et al.  The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway. , 2006, Experimental hematology.

[28]  Satoru Fukuyama,et al.  Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor–β1 , 2006, The Journal of experimental medicine.

[29]  P. Schumacker,et al.  Reactive oxygen species in cancer cells: live by the sword, die by the sword. , 2006, Cancer cell.

[30]  S. Snyder,et al.  Inducible Nitric Oxide Synthase Binds, S-Nitrosylates, and Activates Cyclooxygenase-2 , 2005, Science.

[31]  R. Evans,et al.  Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.

[32]  V. Steele,et al.  Prevention of mouse lung tumors by targretin , 2006, International journal of cancer.

[33]  S. Hilsenbeck,et al.  The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. , 2002, Cancer research.

[34]  Howard L. Weiner,et al.  Inflammation and therapeutic vaccination in CNS diseases , 2002, Nature.

[35]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[36]  M. You,et al.  Prevention of lung cancer progression by bexarotene in mouse models , 2006, Oncogene.

[37]  M. Sporn,et al.  Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. , 2006, Cancer research.

[38]  Paul Talalay,et al.  Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Sporn,et al.  Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. , 2002, Molecular cancer therapeutics.

[40]  T. Guilarte,et al.  In vivo modulation of the Parkinsonian phenotype by Nrf2. , 2006, Neurotoxicology.

[41]  M. Sporn,et al.  Evidence Supporting a Role for Calcium in Apoptosis Induction by the Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO)* , 2004, Journal of Biological Chemistry.

[42]  W. Lamph,et al.  The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. , 2005, Lung cancer.

[43]  P. Džubák,et al.  Pharmacological activities of natural triterpenoids and their therapeutic implications. , 2006, Natural product reports.

[44]  Michael Lehrke,et al.  The Many Faces of PPARγ , 2005, Cell.

[45]  W. El-Deiry,et al.  BRCA1 Transcriptionally Regulates Damaged DNA Binding Protein (DDB2) In the DNA Repair Response Following UV-Irradiation , 2002, Cancer biology & therapy.

[46]  S. O’Rahilly,et al.  PPARγ and human metabolic disease , 2006 .

[47]  M. Sporn,et al.  A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. , 2001, Arthritis and rheumatism.

[48]  M. Sporn,et al.  Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. , 1998, Bioorganic & medicinal chemistry letters.

[49]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[50]  M. D. Leibowitz,et al.  Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids. , 2003, Journal of medicinal chemistry.

[51]  R. Cole,et al.  Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Jonathan Cohen.  The immunopathogenesis of sepsis , 2002, Nature.

[53]  J. Doroshow.  Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. , 2006, Journal of the National Cancer Institute.

[54]  M. Sporn,et al.  The triterpenoid CDDO induces apoptosis in refractory CLL B cells. , 2002, Blood.

[55]  The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. , 2001, Molecular endocrinology.

[56]  M. Sporn,et al.  The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. , 2003, Cancer research.

[57]  M. Boehm,et al.  Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. , 1995, Journal of medicinal chemistry.

[58]  K. Umesono,et al.  A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR , 1991, Cell.

[59]  Albert-László Barabási,et al.  Linked - how everything is connected to everything else and what it means for business, science, and everyday life , 2003 .

[60]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[61]  S. Hilsenbeck,et al.  Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. , 2006, Cancer research.

[62]  M. Sporn,et al.  c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1, 9-Dien-28-Oate in Human Lung Cancer Cells , 2004, Cancer Research.

[63]  W. Lamph,et al.  Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma , 2004, Breast Cancer Research and Treatment.

[64]  M. Sporn,et al.  c-Jun NH 2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3 , 12-Dioxooleana-1 , 9-Dien-28-Oate in Human Lung Cancer Cells , 2004 .

[65]  J. Gutterman,et al.  Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-κB by inhibiting both its nuclear localization and ability to bind DNA , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G. Cohen,et al.  CDDO induces apoptosis via the intrinsic pathway in lymphoid cells , 2004, Leukemia.

[67]  D. Lauffenburger,et al.  A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.

[68]  M. Sporn,et al.  Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL , 2003, Leukemia.

[69]  W. Lamph,et al.  A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours , 2006, British Journal of Cancer.

[70]  Stephanie Birkey Reffey,et al.  Synthetic Triterpenoids Enhance Transforming Growth Factor β/Smad Signaling , 2003 .

[71]  M. Sporn,et al.  An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[72]  A. Dinkova-Kostova,et al.  Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. , 2003, Advances in enzyme regulation.

[73]  M. Sporn,et al.  The synthetic triterpenoid, CDDO-Imidazolide blocks nuclear factor-κB activation through direct inhibition of IκB kinase-beta. , 2006 .

[74]  M. Sporn,et al.  Human Immunodeficiency Virus Type 1-Induced Macrophage Gene Expression Includes the p21 Gene, a Target for Viral Regulation , 2005, Journal of Virology.

[75]  M. Sporn,et al.  Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. , 2006, Biochemical and biophysical research communications.

[76]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[77]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.

[78]  M. Sporn,et al.  Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling. , 2004, Molecular pharmacology.

[79]  Tadashi Honda,et al.  Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. , 2002, Blood.

[80]  M. D. Leibowitz,et al.  Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. , 2006, Endocrinology.

[81]  E. Goldsmith,et al.  Yersinia YopJ Acetylates and Inhibits Kinase Activation by Blocking Phosphorylation , 2006, Science.

[82]  R. Eckert,et al.  Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. , 2004, Carcinogenesis.

[83]  M. Sporn,et al.  The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[84]  M. D. Leibowitz,et al.  Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. , 2003, Journal of medicinal chemistry.

[85]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[86]  M. Konopleva,et al.  2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid and Related Compounds Inhibit Growth of Colon Cancer Cells through Peroxisome Proliferator-Activated Receptor γ-Dependent and -Independent Pathways , 2005, Molecular Pharmacology.

[87]  Michael Karin,et al.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. , 2005, The Journal of clinical investigation.

[88]  H. Xu,et al.  Structure-based design of potent retinoid X receptor alpha agonists. , 2004, Journal of medicinal chemistry.

[89]  L. Hamann,et al.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.

[90]  D. Kufe,et al.  Triterpenoid CDDO-Me Blocks the NF-κB Pathway by Direct Inhibition of IKKβ on Cys-179* , 2006, Journal of Biological Chemistry.

[91]  M. Konopleva,et al.  A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells , 2006, Clinical Cancer Research.

[92]  M. Sporn,et al.  The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. , 2004, Blood.

[93]  H. Daniel,et al.  Olive fruit extracts inhibit proliferation and induce apoptosis in HT-29 human colon cancer cells. , 2006, The Journal of nutrition.

[94]  M. Sporn,et al.  2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer* , 2005, Journal of Biological Chemistry.

[95]  M. Sporn,et al.  The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  M. Sporn,et al.  The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes , 2003, Arthritis research & therapy.

[97]  R. Figlin,et al.  Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  C. B. Pickett,et al.  The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. , 2004, Free radical biology & medicine.

[99]  M. Sporn,et al.  The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. , 2006, Molecular cancer therapeutics.

[100]  M. Sporn,et al.  Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. , 2004, Journal of medicinal chemistry.

[101]  M. Konopleva,et al.  A Novel Mechanism of Action of Methyl-2-cyano-3,12 Dioxoolean-1,9 Diene-28-oate: Direct Permeabilization of the Inner Mitochondrial Membrane to Inhibit Electron Transport and Induce Apoptosis , 2005, Molecular Pharmacology.

[102]  Jason H Bielas,et al.  Generation of mutator mutants during carcinogenesis. , 2006, DNA repair.

[103]  Masayuki Yamamoto,et al.  Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. , 2006, The Journal of clinical investigation.

[104]  E. Winer,et al.  Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Di Chen,et al.  Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. , 2006, Cancer research.

[106]  E. Dmitrovsky,et al.  Bexarotene and erlotinib for aerodigestive tract cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Neil J Ganem,et al.  2-Cyano-3,12-dioxooleana-1,9(11)-diene-28-oic Acid Disrupts Microtubule Polymerization: A Possible Mechanism Contributing to Apoptosis , 2006, Molecular Pharmacology.

[108]  M. Sporn.  Dichotomies in cancer research: some suggestions for a new synthesis , 2006, Nature Clinical Practice Oncology.

[109]  John M Pezzuto,et al.  Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[110]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[111]  John Calvin Reed.  Apoptosis-targeted therapies for cancer. , 2003, Cancer cell.

[112]  C. Benoist,et al.  Mast cells in autoimmune disease , 2002, Nature.

[113]  M. Sporn,et al.  The Novel Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) Potently Enhances Apoptosis Induced by Tumor Necrosis Factor in Human Leukemia Cells* , 2002, The Journal of Biological Chemistry.

[114]  L Zhang,et al.  Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. , 1994, Journal of medicinal chemistry.

[115]  M. Konopleva,et al.  The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. , 2004, The Journal of investigative dermatology.

[116]  Geoffrey A. Cordell,et al.  Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis , 1995, Nature Medicine.

[117]  M. Sporn,et al.  The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor–Negative Model of Breast Cancer , 2006, Clinical Cancer Research.

[118]  Robert A Hegele,et al.  Retinoid X receptor heterodimers in the metabolic syndrome. , 2005, The New England journal of medicine.

[119]  P. Chambon,et al.  Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. , 2006, Endocrinology.

[120]  P. Brown,et al.  Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade , 2006, Breast Cancer Research and Treatment.

[121]  M. Sporn,et al.  Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. , 2000, Journal of medicinal chemistry.

[122]  M. Sporn,et al.  A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. , 2000, Molecular endocrinology.

[123]  M. Sporn,et al.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. , 2007, Cancer research.

[124]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[125]  T. Xia,et al.  Toxic Potential of Materials at the Nanolevel , 2006, Science.

[126]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[127]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[128]  M. Massiah,et al.  Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[129]  M. Sporn,et al.  Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes , 2006, Molecular Cancer Therapeutics.

[130]  M. Konopleva,et al.  The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells , 2005, Leukemia.

[131]  Y. Surh,et al.  Transcriptional regulation via cysteine thiol modification: A novel molecular strategy for chemoprevention and cytoprotection , 2006, Molecular carcinogenesis.

[132]  Y. Lou,et al.  Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. , 1994, Cancer research.

[133]  M. Sporn,et al.  The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β , 2006, Molecular Cancer Therapeutics.

[134]  M. Sporn,et al.  Triterpenoid CDDO-Im downregulates PML/RARα expression in acute promyelocytic leukemia cells , 2005, Cell Death and Differentiation.

[135]  M. Sporn,et al.  The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. , 2001, Molecular pharmacology.

[136]  Natasa Przulj,et al.  High-Throughput Mapping of a Dynamic Signaling Network in Mammalian Cells , 2005, Science.

[137]  M. Sporn,et al.  Chemoprevention: an essential approach to controlling cancer , 2002, Nature Reviews Cancer.

[138]  Laurie A. Minns,et al.  A novel triterpenoid induces transforming growth factor beta production by intraepithelial lymphocytes to prevent ileitis. , 2004, Gastroenterology.

[139]  M. Sporn,et al.  Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[140]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[141]  M. Sporn,et al.  The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells , 2006, Clinical Cancer Research.

[142]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[143]  A. Monks,et al.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.

[144]  J. Lehmann,et al.  Retinoids selective for retinoid X receptor response pathways. , 1992, Science.

[145]  D. Gold,et al.  Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. , 2003, Cancer research.

[146]  R. Jove,et al.  Stat3 regulates genes common to both wound healing and cancer , 2005, Oncogene.

[147]  M. Sporn,et al.  Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. , 2005, Bioorganic & medicinal chemistry letters.

[148]  E. Dmitrovsky,et al.  Nonclassical retinoids and lung carcinogenesis. , 2005, Clinical lung cancer.

[149]  H. Nishino,et al.  Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. , 1988, Cancer research.

[150]  W. Mitzner,et al.  Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice , 2005, The Journal of experimental medicine.

[151]  M. Sporn,et al.  A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. , 1999, Cancer research.

[152]  M. Gottardis,et al.  Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. , 1998, Cancer research.

[153]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[154]  T. Kensler,et al.  Nrf2 as a target for cancer chemoprevention. , 2005, Mutation research.

[155]  J. Letterio.  TGF-β signaling in T cells: roles in lymphoid and epithelial neoplasia , 2005, Oncogene.

[156]  M. Sporn,et al.  Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. , 2004, Molecular cancer therapeutics.

[157]  F. Khuri,et al.  Depletion of ntracellular Glutathione Contributes to JNK-Mediated Death Receptor 5 Upregulation and Apoptosis Induction by the Novel Synthetic Triterpenoid Methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me)1 , 2006, Cancer biology & therapy.

[158]  M. Sporn,et al.  Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy , 2004, Clinical Cancer Research.

[159]  R. Heyman,et al.  Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. , 1999, Journal of the National Cancer Institute.

[160]  M. Konopleva,et al.  A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[161]  R. Lotan,et al.  Apoptosis as a novel target for cancer chemoprevention. , 2004, Journal of the National Cancer Institute.

[162]  T. Finkel.  Radical medicine: treating ageing to cure disease , 2005, Nature Reviews Molecular Cell Biology.

[163]  Jiang Li,et al.  The hypothesis , 1990 .

[164]  L. Altucci,et al.  Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. , 2005, Cancer research.

[165]  M. Konopleva,et al.  Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-γ expression , 2004 .

[166]  M. Sporn,et al.  Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. , 1998, Cancer research.

[167]  M. Sporn,et al.  The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells , 2006, Molecular Cancer Therapeutics.

[168]  Masayuki Yamamoto,et al.  Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. , 2006, Advances in enzyme regulation.

[169]  Y. Surh,et al.  15 -Deoxy -Δ12,14 -prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors , 2006 .

[170]  R. Colavitti,et al.  This Review Is Part of a Thematic Series on New Paradigms of Transcriptional Control of Myocardial and Vascular Growth, Which Includes the following Articles: Redox-dependent Transcriptional Regulation Excitation-transcription Coupling Redox-dependent Transcriptional Regulation Review Mammalian Redo , 2022 .

[171]  W. D. Nes,et al.  Isopentenoids and other natural products : evolution and function , 1994 .